Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

China flag China · Delayed Price · Currency is CNY
52.80
+1.72 (3.37%)
Jul 10, 2026, 3:00 PM CST
Market Cap47.32B +33.3%
Revenue (ttm)4.32B +248.9%
Net Income2.97B +315.2%
EPS3.30 +312.5%
Shares Out 896.23M
PE Ratio16.00
Forward PE73.61
Dividend0.33 (0.65%)
Ex-Dividend DateJun 18, 2026
Volume21,168,273
Open50.28
Previous Close51.08
Day's Range49.01 - 55.95
52-Week Range32.26 - 66.62
Beta0.29
Analystsn/a
Price Targetn/a
Earnings DateAug 21, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,012
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688336
Full Company Profile

Financial Performance

In 2025, SHA:688336's revenue was 4.20 billion, an increase of 251.81% compared to the previous year's 1.19 billion. Earnings were 2.90 billion, an increase of 311.49%.

Financial Statements